KR102150135B1 - 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도 - Google Patents

만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도 Download PDF

Info

Publication number
KR102150135B1
KR102150135B1 KR1020157001458A KR20157001458A KR102150135B1 KR 102150135 B1 KR102150135 B1 KR 102150135B1 KR 1020157001458 A KR1020157001458 A KR 1020157001458A KR 20157001458 A KR20157001458 A KR 20157001458A KR 102150135 B1 KR102150135 B1 KR 102150135B1
Authority
KR
South Korea
Prior art keywords
ferric citrate
iron
patient
increase
ferric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157001458A
Other languages
English (en)
Korean (ko)
Other versions
KR20150036131A (ko
Inventor
엔리끄 포라도수
론 벤트수르
3세 제임스 에프 올리비에로
Original Assignee
케릭스 바이오파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케릭스 바이오파마슈티컬스 인코포레이티드 filed Critical 케릭스 바이오파마슈티컬스 인코포레이티드
Publication of KR20150036131A publication Critical patent/KR20150036131A/ko
Application granted granted Critical
Publication of KR102150135B1 publication Critical patent/KR102150135B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157001458A 2012-06-21 2013-06-21 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도 Active KR102150135B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261662565P 2012-06-21 2012-06-21
US61/662,565 2012-06-21
US201361757229P 2013-01-28 2013-01-28
US61/757,229 2013-01-28
US201361801050P 2013-03-15 2013-03-15
US201361800618P 2013-03-15 2013-03-15
US61/800,618 2013-03-15
US61/801,050 2013-03-15
PCT/US2013/047134 WO2013192565A2 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207024260A Division KR20200103855A (ko) 2012-06-21 2013-06-21 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도

Publications (2)

Publication Number Publication Date
KR20150036131A KR20150036131A (ko) 2015-04-07
KR102150135B1 true KR102150135B1 (ko) 2020-08-31

Family

ID=49769729

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207024260A Ceased KR20200103855A (ko) 2012-06-21 2013-06-21 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도
KR1020157001458A Active KR102150135B1 (ko) 2012-06-21 2013-06-21 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020207024260A Ceased KR20200103855A (ko) 2012-06-21 2013-06-21 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도

Country Status (18)

Country Link
US (3) US20130345303A1 (enExample)
EP (3) EP2863906B1 (enExample)
JP (4) JP2015535209A (enExample)
KR (2) KR20200103855A (enExample)
CN (2) CN113244209A (enExample)
AU (2) AU2013278000A1 (enExample)
BR (1) BR112014032049A2 (enExample)
CA (1) CA2876982A1 (enExample)
DK (1) DK3730136T3 (enExample)
EA (1) EA201590062A1 (enExample)
ES (2) ES2796254T3 (enExample)
HK (1) HK1214503A1 (enExample)
IL (1) IL236356A0 (enExample)
MX (1) MX2014015615A (enExample)
NO (1) NO2025048I1 (enExample)
PL (1) PL3730136T3 (enExample)
SG (2) SG10201805177PA (enExample)
WO (1) WO2013192565A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2563819C2 (ru) 2009-07-21 2015-09-20 Керикс Байофармасьютикалз, Инк. Лекарственные формы цитрата железа (iii)
TWI653043B (zh) * 2012-12-20 2019-03-11 瑞士商伊蘭科動物健康公司 新用途
HRP20171590T1 (hr) 2013-06-05 2017-12-29 Tricida Inc. Polimeri koji vežu protone za oralnu primjenu
ES2856261T3 (es) * 2013-10-01 2021-09-27 Fresenius Medical Care Deutschland Gmbh Método y aparatos para determinar una pérdida diaria de hierro de un paciente
JP2016535780A (ja) * 2013-11-04 2016-11-17 ケリク バイオファーマシューティカルス， インコーポレーテッド 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
WO2015110968A1 (en) * 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
PL3229816T3 (pl) 2014-12-10 2020-09-21 Tricida Inc. Polimery wiążące protony do podawania doustnego
HK1248589A1 (zh) * 2015-03-04 2018-10-19 凯克斯生物制药公司 柠檬酸铁在治疗缺铁性贫血中的用途
CN104688706B (zh) * 2015-04-01 2017-07-14 成都欣捷高新技术开发有限公司 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法
WO2016162794A1 (en) * 2015-04-08 2016-10-13 Leiutis Pharmaceuticals Pvt Ltd Pharmaceutical compositions of ferric citrate
WO2016162888A1 (en) * 2015-04-09 2016-10-13 Actavis Group Ptc Ehf. Process for preparing pharmaceutical grade ferric citrate
EP3452028A4 (en) 2016-05-06 2020-04-15 Tricida Inc. COMPOSITIONS AND METHOD FOR TREATING ACID-BASED DISORDERS
JP7387435B2 (ja) 2017-09-19 2023-11-28 日本たばこ産業株式会社 過多月経患者及び／又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び／又は治療におけるクエン酸第二鉄の使用
AU2018360867B2 (en) 2017-11-03 2024-12-12 Tricida, Inc. Compositions for and method of treating acid-base disorders
WO2019236639A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
EP3873492A1 (en) 2018-10-29 2021-09-08 Pharmacosmos Holding A/s Treating iron deficiency with ferric carboxymaltose
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
TW202313072A (zh) 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物
CN115024495B (zh) * 2022-06-27 2024-03-22 北京金康普食品科技有限公司 改善肾病患者钙磷代谢的营养组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186939A1 (en) * 2006-01-30 2009-07-23 Keith Chan Method of Treating Chronic Kidney Disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180094B1 (en) * 1996-07-19 2001-01-30 Nikken Chemicals Co., Ltd. Remedies for hyperphosphatemia
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
CN1600302A (zh) * 2003-09-22 2005-03-30 宝龄富锦生技股份有限公司 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
HUE025264T2 (en) 2005-08-18 2016-02-29 Panion & Bf Biotech Inc Pharmaceutical-grade ferric citrate for medical use
PT1973549T (pt) * 2006-01-06 2016-10-25 Luitpold Pharm Inc Métodos e composições para administração de ferro
RU2563819C2 (ru) * 2009-07-21 2015-09-20 Керикс Байофармасьютикалз, Инк. Лекарственные формы цитрата железа (iii)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186939A1 (en) * 2006-01-30 2009-07-23 Keith Chan Method of Treating Chronic Kidney Disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Nephrol. 2006, 19(2), pp. 161-167 중 초록*
Renal & Urology News, 2009.12.17.*

Also Published As

Publication number Publication date
BR112014032049A2 (pt) 2017-07-25
EP2863906B1 (en) 2020-03-18
SG10201805177PA (en) 2018-07-30
EP3730136B1 (en) 2023-12-27
EP3730136A1 (en) 2020-10-28
KR20150036131A (ko) 2015-04-07
CN104884055A (zh) 2015-09-02
US20150079168A1 (en) 2015-03-19
WO2013192565A3 (en) 2015-10-15
DK3730136T3 (da) 2024-01-22
ES2796254T3 (es) 2020-11-26
JP2022070945A (ja) 2022-05-13
AU2018203205B2 (en) 2020-03-12
EA201590062A1 (ru) 2016-02-29
US20130345303A1 (en) 2013-12-26
JP2020100638A (ja) 2020-07-02
HK1210013A1 (en) 2016-04-15
AU2013278000A1 (en) 2015-01-22
EP2863906A2 (en) 2015-04-29
CN113244209A (zh) 2021-08-13
NO2025048I1 (no) 2025-11-06
MX2014015615A (es) 2015-03-20
PL3730136T3 (pl) 2024-03-25
KR20200103855A (ko) 2020-09-02
EP4335436A3 (en) 2024-05-15
WO2013192565A2 (en) 2013-12-27
HK1214503A1 (zh) 2016-07-29
JP2018138562A (ja) 2018-09-06
JP2015535209A (ja) 2015-12-10
CA2876982A1 (en) 2013-12-27
AU2018203205A1 (en) 2018-05-31
SG11201408521WA (en) 2015-01-29
US20140234416A1 (en) 2014-08-21
ES2970050T3 (es) 2024-05-24
IL236356A0 (en) 2015-02-26
EP4335436A2 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
KR102150135B1 (ko) 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도
JP6828100B2 (ja) 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
KR20160105499A (ko) 철 트리말톨의 복용량 양생법
US20240041816A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
US20190269645A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
HK1210013B (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524A (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150120

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180621

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191029

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200525

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200824

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200825

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200825

End annual number: 3

Start annual number: 1

PG1601 Publication of registration